Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Amide compounds, preparation method and medical use thereof

A compound and pharmaceutical technology, applied in the preparation of organic compounds, carboxylic acid amide preparation, chemical instruments and methods, etc., can solve the problem of low activity of small molecule inhibitors, poor membrane permeability, poor physical and chemical properties of peptidomimetic compounds, etc. question

Active Publication Date: 2015-12-23
CHINA PHARM UNIV
View PDF3 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, research on inhibitors of MLL1-WDR5 protein-protein interaction is still in its infancy. The only inhibitors under research are peptidomimetics and a class of small molecule compounds, but peptidomimetic compounds have poor physical and chemical properties and poor membrane permeability. Poor, small molecule inhibitor activity is not high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amide compounds, preparation method and medical use thereof
  • Amide compounds, preparation method and medical use thereof
  • Amide compounds, preparation method and medical use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Synthesis of N-(2-(4-methylpiperazine)-5-cyanophenyl)-2-chloro-3-methoxybenzenesulfonamide (1):

[0043] In a 25ml eggplant-shaped bottle, 1.0g (6.4mmol) of 2-fluoro-5-cyanoaniline was dissolved in anhydrous dichloromethane, and 2.3g (9.6mmol) of 2-chloro-3-methanol was added dropwise at room temperature. Dichloromethane solution of oxybenzenesulfonyl chloride, and then add 0.77ml (9.6mmol) of pyridine, and react overnight at room temperature. The reaction solution was spin-dried and column chromatographed to obtain 0.97 g of intermediate E as a light yellow solid (yield 48.5%).

[0044] Put 0.2g (0.61mmol) of the above solid in a 25ml eggplant-shaped bottle, dissolve it in 5ml DMF, add 0.088ml (0.8mmol) N-methylpiperazine, then add catalyst 0.14ml (0.8mmol) DIPEA, and react at 80°C for 3 After one hour, the reaction solution was diluted with 40 ml of ethyl acetate, washed twice with water, and the organic phase was collected and chromatographed to obtain 10.15 g of a ...

Embodiment 2

[0047] Synthesis of N-(2-fluoro-4-methoxyphenyl)-2-(4-methylhomopiperazine)-5-cyanophenylsulfonamide (2):

[0048] Using 2-fluoro-5-cyanobenzenesulfonyl chloride, 2-fluoro-4-methoxyaniline, and N-methylhomopiperazine as raw materials, according to the similar method of Example 1, compound 2 was synthesized, and two steps were obtained. rate 30.5%.

[0049] 1 HNMR (300MHz, CDCl 3 )δ8.22(s,1H),7.91(s,1H),7.81(d,J=7.3Hz,1H),7.08(d,J=8.4Hz,1H),6.98(d,J=7.7Hz, 2H),5.28(brs,1H),3.86(s,3H),3.28(t,J=4.3Hz,4H),3.02(m,2H),2.90(m,2H),2.70(s,3H), 1.87(m,2H).

Embodiment 3

[0051] Synthesis of N-(2-(4-methylpiperazine)-5-trifluoromethylphenyl)-2,4,6-trimethylbenzenesulfonamide (3):

[0052] Using 2-fluoro-5-trifluoromethylaniline, 2,4,6-trimethylbenzenesulfonyl chloride, and N-methylpiperazine as raw materials, compound 3 was synthesized according to the method similar to Example 1, two steps Yield 29.2%.

[0053] 1 HNMR (300MHz, CDCl 3 )δ7.98(d, J=2.5Hz, 1H), 7.86(dd, J=8.7, 2.5Hz, 2H), 7.23(d, J=8.7Hz, 1H), 6.98(s, 2H), 3.01( brs,4H),2.73(brs,10H),2.50(brs,4H),2.48(s,3H),2.28(s,3H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of pharmaceutical chemistry, particularly a group of amide compounds (I) and a preparation method therefor and use thereof. Pharmacodynamic experiments prove that the compounds of the invention can be used for preparing medicines for treating leukemia. The formula (I) is shown in the description.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to a group of amide compounds and their preparation method and application. The compounds of the invention can be used to prepare medicines for treating leukemia. Background technique [0002] The gene translocation and rearrangement of the 4-position lysine (H3K4) methyltransferase MLL1 of histone H3 forms a fusion gene, expressing MLL fusion protein, which can cause acute myelogenous leukemia (AML) and acute lymphoblastic leukemia Mixed lineage leukemia (ALL). Among them, leukemia caused by MLL1 abnormality accounts for 5-10% of adult AML leukemia and 70% of neonatal ALL leukemia. MLL leukemia has unique clinical characteristics, conventional chemotherapy is unsatisfactory, and the prognosis is poor. Therefore, it is necessary to develop new treatments and drugs for the biological properties of leukemia caused by MLL abnormalities. The occurrence of mixed lineage leukemia requ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C255/60C07C253/30C07C237/40C07C231/14C07C233/80C07D295/155C07D243/08C07D295/096C07D295/135C07D213/74C07D295/13C07D233/61C07D239/26C07D213/56C07C279/12C07C277/08A61K31/495A61K31/551A61K31/277A61K31/167A61K31/496A61K31/40A61K31/506A61P35/02
Inventor 尤启冬孙昊鹏李冬冬陈维琳郭小可张晓进徐晓莉
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com